An analyst has reiterated that Selecta Biosciences' portfolio is “promising” despite the biotech offloading a quarter of its workforce along with non-partnered gene therapy programs.

Selecta Biosciences is jumping into Cartesian’s cell therapy cockpit, preparing to take flight once again after landing nearly all of its previous programs. The two companies announced a reverse ...

WATERTOWN, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic ...

(RTTNews) - Selecta Biosciences, Inc. (SELB) announced Monday that it has merged with biotechnology company Cartesian Therapeutics, Inc. In connection with the merger, Selecta announced a $60.25 ...

WATERTOWN, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic ...

Sobi licensed rights to its gout drug candidate, SEL-212, from Selecta Biosciences. The drug employs pegadricase, a yeast-derived enzyme, to break down excess urate. However, this enzyme can spark ...